PMID- 34376997
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210812
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 14
DP  - 2021
TI  - Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an 
      ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI 
      Therapy: A Case Report.
PG  - 4329-4333
LID - 10.2147/OTT.S315832 [doi]
AB  - Anaplastic lymphoma kinase (ALK) rearrangement is extremely rare in lung squamous 
      cell carcinoma (LSCC), and it remains controversial as to whether LSCC patients 
      with ALK rearrangement can benefit from ALK tyrosine kinase inhibitors (TKIs). 
      Here, we report an LSCC patient with ALK rearrangement who was treated with 
      sequential ALK TKI therapies and experienced a clinical benefit of 35 months. 
      Although the use of ALK TKIs showed clinical benefits, targeted next-generation 
      sequencing (NGS) for dynamic monitoring of circulating tumor DNA (ctDNA) from 
      patient plasma revealed the accumulation of ALK resistance mutations, which could 
      provide valuable information in designing the treatment strategy. Our study 
      highlights the importance of dynamic monitoring of ctDNA using NGS to discover 
      tumor evolution to guide treatment decision-making and provides meaningful 
      insights into the potential treatment options for ALK-positive LSCC patients.
CI  - (c) 2021 Yao et al.
FAU - Yao, Bin
AU  - Yao B
AD  - Department of Radiotherapy and Chemotherapy, The Affiliated People's Hospital of 
      Ningbo University, Ningbo, Zhejiang, People's Republic of China.
FAU - Han, Xue
AU  - Han X
AD  - Department of Research and Development, Nanjing Geneseeq Technology Inc., 
      Nanjing, Jiangsu, People's Republic of China.
FAU - Pang, Linrong
AU  - Pang L
AD  - Department of Radiotherapy and Chemotherapy, The Affiliated People's Hospital of 
      Ningbo University, Ningbo, Zhejiang, People's Republic of China.
FAU - Xu, Caihong
AU  - Xu C
AD  - Department of Radiotherapy and Chemotherapy, The Affiliated People's Hospital of 
      Ningbo University, Ningbo, Zhejiang, People's Republic of China.
FAU - Liu, Sisi
AU  - Liu S
AD  - Department of Research and Development, Nanjing Geneseeq Technology Inc., 
      Nanjing, Jiangsu, People's Republic of China.
FAU - Cheng, Xiaochun
AU  - Cheng X
AD  - Department of Radiotherapy and Chemotherapy, The Affiliated People's Hospital of 
      Ningbo University, Ningbo, Zhejiang, People's Republic of China.
FAU - Chen, Jun
AU  - Chen J
AD  - Department of Radiotherapy and Chemotherapy, The Affiliated People's Hospital of 
      Ningbo University, Ningbo, Zhejiang, People's Republic of China.
LA  - eng
PT  - Case Reports
DEP - 20210803
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC8349191
OTO - NOTNLM
OT  - ALK rearrangement
OT  - dynamic monitoring
OT  - next-generation sequencing
OT  - resistance mutation
COIS- Xue Han and Sisi Liu are employees of Nanjing Geneseeq Technology Inc., China. 
      The authors report no other conflicts of interest to declare.
EDAT- 2021/08/12 06:00
MHDA- 2021/08/12 06:01
PMCR- 2021/08/03
CRDT- 2021/08/11 06:34
PHST- 2021/04/14 00:00 [received]
PHST- 2021/07/21 00:00 [accepted]
PHST- 2021/08/11 06:34 [entrez]
PHST- 2021/08/12 06:00 [pubmed]
PHST- 2021/08/12 06:01 [medline]
PHST- 2021/08/03 00:00 [pmc-release]
AID - 315832 [pii]
AID - 10.2147/OTT.S315832 [doi]
PST - epublish
SO  - Onco Targets Ther. 2021 Aug 3;14:4329-4333. doi: 10.2147/OTT.S315832. eCollection 
      2021.